Want to see HK:1312 full AI Analyst Report?
Top Page
Kontafarma China Holdings Ltd
(1312)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$0.03
▼(-10.00% Downside)
Action:Reiterated
Date:08/20/26
The score is held back primarily by weak profitability and sharply widening net losses despite strong gross margins, which also pressured equity and returns. Offsetting this, cash flow has improved and leverage has declined, reducing balance-sheet risk. Technically the stock shows mild positive momentum, while valuation is hard to judge given negative earnings and no dividend yield data.
Positive Factors
Strong Gross Margins
Consistently high gross margins indicate that the company retains meaningful value after direct costs, supported by pricing or product-mix advantages stated in the financial analysis. If maintained, this provides a foundation for restoring operating profitability once cost control and operating leverage improve.
Negative Factors
Deepening Net Losses
The sharp deterioration in net profitability is a durable concern because it directly weakens retained equity and limits the company’s ability to reinvest from earnings. Unless the underlying costs, charges, or operating inefficiencies improve, recurring losses could continue to erode financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Consistently high gross margins indicate that the company retains meaningful value after direct costs, supported by pricing or product-mix advantages stated in the financial analysis. If maintained, this provides a foundation for restoring operating profitability once cost control and operating leverage improve.
Read all positive factors
Kontafarma China Holdings Ltd (1312) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$150.63M
Dividend Yield2.96%
Average Volume (3M)358.80K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth-5.20%
EPS Growth41.38%
CountryHK
Employees625
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.04
Shares Outstanding5,588,572,000
10 Day Avg. Volume39,000
30 Day Avg. Volume358,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.18
P/FCF Ratio3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kontafarma China Holdings Ltd Business Overview & Revenue Model
Company Description
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory...
Kontafarma China Holdings Ltd Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
46
Neutral
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 845.33M | 914.71M | 897.52M | 809.11M | 894.06M | 803.27M |
| Gross Profit | 437.76M | 513.64M | 516.16M | 471.29M | 506.22M | 396.18M |
| EBITDA | 12.29M | -151.75M | 6.71M | 78.50M | 36.29M | 25.23M |
| Net Income | -212.80M | -427.85M | -75.54M | -28.84M | -41.55M | -15.05M |
Balance Sheet | ||||||
| Total Assets | 997.37M | 1.07B | 1.59B | 1.73B | 2.12B | 2.56B |
| Cash, Cash Equivalents and Short-Term Investments | 67.62M | 66.06M | 90.58M | 87.66M | 142.59M | 183.96M |
| Total Debt | 189.76M | 203.68M | 297.19M | 333.82M | 590.72M | 728.95M |
| Total Liabilities | 579.08M | 588.92M | 625.90M | 665.39M | 964.16M | 1.22B |
| Stockholders Equity | 510.20M | 553.26M | 978.70M | 1.06B | 1.10B | 1.19B |
Cash Flow | ||||||
| Free Cash Flow | 9.57M | 53.15M | 33.41M | 12.92M | -53.84M | -49.31M |
| Operating Cash Flow | 29.21M | 76.68M | 47.05M | 37.12M | -2.17M | 75.07M |
| Investing Cash Flow | 6.65M | 8.82M | -6.01M | 144.14M | 121.53M | 23.24M |
| Financing Cash Flow | -56.89M | -90.16M | -42.52M | -198.81M | -137.33M | -99.80M |
Kontafarma China Holdings Ltd Technical Analysis
Negative
0.03
Price Trends
0.03
Negative
0.03
Positive
0.03
Positive
Market Momentum
>-0.01
Negative
48.24
Neutral
73.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1312, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1312.
Kontafarma China Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$36.11B | 10.79 | 7.71% | 4.51% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$739.99M | 2.14 | 1.79% | 2.05% | ― | ― | |
49 Neutral | HK$150.63M | -0.71 | -40.02% | 2.96% | -5.20% | 41.38% | |
45 Neutral | HK$45.52M | -0.73 | -18.70% | 4.32% | 43.00% | -74.41% | |
43 Neutral | HK$21.60B | -2.19 | -5.48% | 6.02% | 0.12% | -214.59% | |
42 Neutral | HK$505.27M | -0.10 | 98.32% | 2.20% | ― | ― |
* Healthcare Sector Average
HK:1312
Kontafarma China Holdings Ltd
0.03
>-0.01
-6.90%
HK:3323
China National Building Material Co
2.85
-2.48
-46.55%
HK:0868
Xinyi Glass Holdings
8.10
-0.66
-7.51%
HK:3300
China Glass Holdings Limited
0.30
-0.16
-34.78%
HK:1252
China Tianrui Group Cement Co., Ltd.
0.24
-0.08
-23.81%
HK:1847
YCIH Green High-Performance Concrete Co., Ltd. Class H
0.34
-0.30
-46.88%
Kontafarma China Holdings Ltd Corporate Events
Kontafarma China Wins Second Waiver on Delayed Lease Circular
Sep 24, 2026
Kontafarma China Holdings Limited has received a second waiver from the Hong Kong Stock Exchange allowing a further extension to dispatch a shareholder circular related to the renewal of a lease for its fitness and yoga centre. The circular, which...
Kontafarma Moves to Liquidate Loss-Making Singapore Fitness Subsidiaries
Sep 10, 2026
Kontafarma China Holdings Ltd has disclosed that its indirect Singapore subsidiaries True Fitness Pte. Ltd. and True Yoga Pte. Ltd. have passed resolutions to initiate creditors’ voluntary winding-up under Singapore’s Insolvency, Restr...
Kontafarma China Seeks Second Waiver as Lease Circular Faces Further Delay
Sep 4, 2026
Kontafarma China Holdings, a Cayman Islands-incorporated company listed in Hong Kong, operates fitness and yoga centres and manages significant lease arrangements tied to these facilities. The group is overseen by a board led by Chairman Wang Limi...
Kontafarma China Narrows Interim Loss Despite Revenue Decline
Aug 28, 2026
Kontafarma China Holdings reported unaudited interim results for the six months ended June 30, 2026, showing revenue of HK$383.3 million, down from HK$452.7 million a year earlier. The group’s gross profit fell to HK$178.7 million, and it re...
Kontafarma Reshapes Top Management With New President and Executive Director
Aug 17, 2026
Kontafarma China Holdings Ltd has announced an internal reshuffle in its senior management, with chairman and executive director Wang Limin stepping down as president of the group while retaining his board roles and chairmanship of key governance ...
Kontafarma China Refines Board and Committee Structure for Stronger Governance
Aug 17, 2026
Kontafarma China Holdings Ltd has updated its board composition effective 17 August 2026, confirming a seven-member Board comprising four executive directors and three independent non-executive directors. Wang Limin serves as chairman, supported b...
Kontafarma China Delays Circular on Major Fitness Centre Lease Renewal
Aug 17, 2026
Kontafarma China Holdings Limited has postponed the despatch of a shareholder circular relating to the renewal of a lease for an existing fitness and yoga centre, classified as a major transaction under Hong Kong listing rules. The circular, origi...
Kontafarma China Sets August Board Meeting to Review Interim Results and Dividend
Aug 17, 2026
Kontafarma China Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, is guided by a seven-member board featuring four executive directors and three independent non-executive directors. The team is led by Chairman Wang Lim...
Kontafarma Flags Smaller First-Half Loss Amid Fresh Singapore Fitness Impairments
Aug 17, 2026
Kontafarma China Holdings has warned that it expects to post a consolidated net loss of between HK$67.2 million and HK$100.7 million for the six months ended 30 June 2026, a substantial improvement from the HK$321.4 million loss a year earlier. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.